Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 405,732	$ 1,872
Prepaid expenses and other current assets	3,745	2,055
Total current assets	409,477	3,927
Operating lease right-of-use assets	28,222	2,165
Restricted cash	567
Property and equipment, net	10,379	3,368
Other non-current assets	4,391	783
Total assets	453,036	10,243
Current liabilities:
Accounts payable	5,013	3,483
Accrued clinical and research and development expenses	7,242	1,646
Accrued expenses and other current liabilities	6,629	3,391
Operating lease liabilities, current	2,278	1,006
Convertible notes-related party		11,635
Convertible notes		9,619
Derivative liabilities		12,705
Financial commitment liabilities-related party		412
Financial commitment liabilities		240
Total current liabilities	21,162	44,137
Operating lease liabilities, non-current	26,263	1,092
Other non-current liabilities	225	250
Total liabilities	47,650	45,479
Commitments and contingencies (Note 13)
Stockholders' equity (deficit):
Convertible preferred stock, $0.001 par value; 11,000,000 shares authorized and 810,700 issued and outstanding at December 31, 2022 (aggregate liquidation preference of $11,000 at December 31, 2022)		1
Common stock, $0.001 par value; 500,000,000 and 29,000,000 shares authorized at December 31, 2023 and 2022, respectively; 41,205,551 and 1,091,800 shares issued and outstanding at December 31, 2023 and 2022, respectively	41	1
Additional paid-in capital	550,491	11,761
Accumulated deficit	(145,146)	(46,999)
Total stockholders' equity (deficit)	405,386	(35,236)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 453,036	$ 10,243